2017
Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non–Vitamin K Antagonist Oral Anticoagulants Before Stroke
Xian Y, Federspiel J, Hernandez A, Laskowitz D, Schwamm L, Bhatt D, Smith E, Fonarow G, Peterson E. Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non–Vitamin K Antagonist Oral Anticoagulants Before Stroke. Circulation 2017, 135: 1024-1035. PMID: 28119380, DOI: 10.1161/circulationaha.116.023940.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravenousAgedAged, 80 and overAnticoagulantsDabigatranFemaleFibrinolytic AgentsHemorrhageHospital MortalityHumansInternational Normalized RatioMalePyrazolesPyridonesRecombinant ProteinsRegistriesRetrospective StudiesRisk FactorsRivaroxabanStrokeTime FactorsTissue Plasminogen ActivatorTreatment OutcomeWarfarinConceptsIntravenous rt-PASymptomatic intracranial hemorrhageIschemic strokeRt-PAIntracranial hemorrhageOdds ratioNon-Vitamin K Antagonist Oral AnticoagulantsIntravenous recombinant tissue plasminogen activatorK Antagonist Oral AnticoagulantsRecombinant tissue plasminogen activatorGuidelines-Stroke registrySerious systemic hemorrhageAcute ischemic strokeAdjusted odds ratioAmerican Heart AssociationTissue plasminogen activatorOutcomes of useHospital mortalityRegistry hospitalsOral anticoagulantsSevere strokeAdverse eventsProhibitive riskRankin ScaleThrombolytic therapy
2012
Safety of full-dose intravenous recombinant tissue plasminogen activator followed by multimodal endovascular therapy for acute ischemic stroke
Nogueira R, Yoo A, Masrur S, Batista L, Hakimelahi R, Hirsch J, Schwamm L. Safety of full-dose intravenous recombinant tissue plasminogen activator followed by multimodal endovascular therapy for acute ischemic stroke. Journal Of NeuroInterventional Surgery 2012, 5: 298. PMID: 22705875, DOI: 10.1136/neurintsurg-2012-010376.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBrain IschemiaCombined Modality TherapyEndovascular ProceduresFemaleHumansInjections, IntravenousMaleMiddle AgedProspective StudiesRecombinant ProteinsRetrospective StudiesStrokeThrombolytic TherapyTissue Plasminogen ActivatorTreatment OutcomeYoung AdultConceptsMultimodal endovascular therapySymptomatic intracranial hemorrhageIntravenous recombinant tissue plasminogen activatorRecombinant tissue plasminogen activatorEndovascular therapyTissue plasminogen activatorParenchymal hematomaSafety endpointHospital dischargeFunctional outcomeFull-dose intravenous recombinant tissue plasminogen activatorPlasminogen activatorIndependent functional outcomeIntravenous rt-PAPrimary safety endpointRt-PA dosageSecondary safety endpointSevere systemic bleedingSimilar safety profileAcute ischemic strokeRate of recanalizationClinical efficacy endpointsT-PA doseBridging therapyGroin hematoma